Login to Your Account

Clinic Roundup

Thursday, February 2, 2012
• Athersys Inc., of Cleveland, reported results from its Phase I trial of MultiStem in patients undergoing hematopoietic stem cell transplants (HCSTs) for leukemia and related conditions, which showed that the cell therapy product was well tolerated in both the single-infusion and repeat-infusion arms. Data also suggested that the therapy might provide benefit to patients of allogeneic HSCT, such as reducing the incidence and severity of graft-vs.-host disease (GvHD) as compared to historical clinical experience. MultiStem has orphan drug designation for the prevention of GvHD.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription